Innate Pharma SA announces that it has acquired the worldwide exclusive development and commercial rights to IPH2101 from Novo Nordisk A/S in the context of a swap of products.
| PR in english | 54.99 KB |
| CP en français | 52.2 KB |
| Slideshow at Eurobio, in english | 403.9 KB |